DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Clinical trial NCT04567420 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04567420
- Sponsor
- Criterium, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-09
- Primary completion
- 2027-12-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.